References
Infections (%)
Peripheral neuropathy (%)
Neutropenia (%)
Thrombo-cytopenia (%)
Thrombo-embolic events (%)
Our pts.
7
2
5
7
2
Cavo et al. [11]
3
10
NR
NR
3
Rosinol et al. [12]
21
14
10
8
12
Moreau et al. [13]
10
3
0
3
2
Kaufman et al. [14]
0
9
0
2
4
NR: Not Reported.
Table 3b:
Grade III/IV toxicities associated with VTD-induction therapy - Comparison to the results of other VTD-trials.
